Could a cancer drug shrink recurrent brain tumors?

NCT ID NCT03220646

Ongoing Disease control Sponsor: Memorial Sloan Kettering Cancer Center Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This phase 2 trial is testing the drug abemaciclib in people whose primary brain tumors have come back after initial treatment. The goal is to see if the drug can shrink tumors or slow their growth. Participants take abemaciclib pills twice daily, and some take it before surgery to study its effects on tumor tissue.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: abemaciclib
What this could lead to: If effective, abemaciclib could offer a new treatment option for patients with recurrent brain tumors, potentially shrinking tumors or delaying further growth.
What could go wrong: This is an early-phase trial with a small number of participants, so results may not apply broadly. The drug may cause side effects or fail to show benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BRAIN TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

astrocytoma (excluding glioblastoma) brain cancer brain neoplasm ependymoma glioma grade II glioma grade III glioma meningioma oligodendroglioma primary central nervous system lymphoma schwannoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BRAIN TUMOR

Contacts and locations

Show contact details

Locations

Hartford Healthcare Cancer Institute @ Hartford Hospital (Data collection only)

Hartford, Connecticut, 06102, United States
Lehigh Valley Health Network

Allentown, Pennsylvania, 18103, United States
Memorial Sloan Kettering Basking Ridge (All Protocol Activities)

Basking Ridge, New Jersey, 07920, United States
Memorial Sloan Kettering Bergen (All Protocol Activities)

Montvale, New Jersey, 07645, United States
Memorial Sloan Kettering Cancer Center (All Protocol Activities)

New York, New York, 10065, United States
Memorial Sloan Kettering Commack (All Protocol Activities)

Commack, New York, 11725, United States
Memorial Sloan Kettering Monmouth (All Protocol Activities)

Middletown, New Jersey, 07748, United States
Memorial Sloan Kettering Westchester (All Protocol Activities)

Harrison, New York, 10604, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.